[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-endothelial-growth-factor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-endothelial-growth-factor":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100591776",false,"NCT06984822","Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant","Evaluation of Serum and Ocular Coherence Tomography Biomarkers in Patients With Diabetic Macular Edema Treated With Anti-VEGF or Dexamethasone Implant","BiomarkerOCT","Inclusion Criteria:\n\n* Type I or type II DM.\n* DME involving the center of the fovea with CFT more than 280 microns and the presence of intraretinal cysts.\n\nExclusion Criteria:\n\n* Prior history of any other macular disease.\n* Previous treatment with dexamethasone implants in the last six months for those in the anti-VEGF group.\n* Previous treatment with anti-VEGF in the last two months for those in the dexamethasone implant group.\n* Prior vitreoretinal surgery.\n* Previous laser treatment of the macula.\n* Previous panretinal photocoagulation.\n* Ocular surgery in the previous 3 months.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).",[26,27,28,29,30,31,32],"Diabetic Macular Edema","Visual Impairment","Diabetes Mellitus","Hyperglycaemia (Diabetic)","Oxidative Stress","Vascular Endothelial Growth Factor","VEGF",[34],"optical coherence tomography","RECRUITING","2025-11-17",{"date":38,"type":39},"2025-11-21","ACTUAL",{"date":41,"type":39},"2025-08-01",{"date":43,"type":20},"2028-12-31",{"name":45,"class":46},"Vastra Gotaland Region","OTHER_GOV",2,""]